Deals: A Copy Cat Play with Merck in Wings
In our M&A Roundup for the week ended March 8, another solid combination of resources, energy, and pharma deals — on the eve of today's Schering-Plough announcement.
View ArticleDeals: Pharma Is the Cure for M&A's Blahs
In our M&A Roundup for the week ended March 15, Merck-Schering is followed — at a distance — by Gilead Sciences buying CV Therapeutics. Behind them, an eclectic mix.
View ArticleDeals: Fertilizer, Roller Coasters, and Gold
In our M&A Roundup for the week ended March 22, a diverse lot of billion-dollar deals helps keep the totals respectable — though far short of the prior "Merck Week."
View ArticleDeals: There Will Be Oil ... in Calgary, Anyway
In our M&A Roundup for the week ended March 29, Suncor's $18.39-billion purchase of Petro-Canada tops the sale of Calgary-based Oilexco's North Sea assets. Deloitte, Time Warner also do some buying.
View ArticleDeal With It
Banks aren't lending, investor defaults are looming, and mark-to-market is a pain. But private equity CFOs are forging a path through the downturn.
View ArticleStrategic Buyers Still in the Catbird Seat
Today's M&A market remains weak, but strategic buyers will lead a pickup in deal activity in 2010, according to a new survey of dealmakers.
View ArticleWaiting for the IPO
Finance chiefs eager to take their companies public in 2010 must weigh a host of factors.
View ArticleLinkedIn Builds a Facebook for Grown-Ups
The networking company's first-quarter revenue more than doubles as it hones in on professionals and professional services.
View ArticleWelcome to the IP Bubble
As tech companies buy and sell patents for escalating sums of money, it's beginning to look a lot like a bubble. What should CFOs do to value their companies' intellectual property accurately and...
View Article
